The Craze Behind Weight-Loss Injectables
By Serena Patel OMS IV In 2012, Novo Nordisk synthesized a compound called semaglutide in an effort to increase the half-life of its counterpart drug liraglutide. These glucagon-like-peptide-1 receptor agonists, originally formulated for patients with Type 2 diabetes, work by promoting the release of insulin to decrease glucose levels. Liraglutide is a daily injectable, while semaglutide is a weekly injectable. The diabetes community had been waiting for a drug like